Dinutuximab beta

BODY-SURFACE-AREA DOSING, NOT WEIGHT-BASED — every figure above is per m2, not per kg; do not run these numbers through a per-kilogram weight calculator. PRE-COURSE GATE: before starting each course, evaluate pulse oximetry, bone marrow, liver and renal function and delay treatment until the thresholds in the monitoring list are reached. DOSE MODIFICATION: based on the physician's assessment of adverse-reaction severity, patients may undergo a 50% dose reduction or a temporary interruption of the infusion; the infusion period is then prolonged or, if tolerated, the infusion rate may be increased up to 3 mL/h (continuous infusion) in order to administer the total dose. Grade 1-2 reactions: decrease infusion rate to 50%, resume at original rate after resolution. Hypersensitivity such as hypotension: interrupt, give supportive measures, resume at original rate after resolution. Dilated pupils with sluggish light reflex with or without photophobia: interrupt, resume at 50% rate after resolution. Any grade 3 or above: interrupt and give supportive measures, resume at 50% rate if the reaction resolves or improves to grade 1-2, then increase to the original rate after resolution; if recurrent, discontinue the infusion and resume the next day if it resolves. Hypersensitivity such as bronchospasm or angioedema: interrupt immediately, treat appropriately, resume treatment for subsequent courses. Capillary leak syndrome: interrupt and give supportive measures, resume at 50% rate if it resolves or improves to grade 1-2. Central neurotoxicity: interrupt immediately, rule out other influencing factors and treat appropriately — there is limited data on resuming treatment and no recommendation can be made. PERMANENT DISCONTINUATION is required for grade 3 or 4 anaphylaxis; prolonged grade 2 peripheral motor neuropathy; grade 3 peripheral neuropathy; grade 3 vision eye toxicity; grade 4 hyponatraemia (below 120 mEq/L) despite appropriate fluid management; recurrent or grade 4 capillary leak syndrome requiring ventilator support; severe central neurotoxicity (grade 3 or 4 with substantial prolonged neurological deficit without detectable reason, recurrent grade 1-3 neurotoxicity, or permanent neurological deficit); and all grades of posterior reversible encephalopathy syndrome and transverse myelitis. CONCOMITANT IL-2 (when combined): subcutaneous injections of 6 x 10^6 IU/m2/day for 2 periods of 5 consecutive days, giving an overall dose of 60 x 10^6 IU/m2 per course; the first 5-day period starts 7 days before the first dinutuximab beta infusion and the second starts concurrently with the dinutuximab beta infusion (days 1 to 5 of each course). MANDATORY ANALGESIC PREMEDICATION (SPC §4.4 — neuropathic pain usually occurs at the beginning of treatment and premedication with analgesics including intravenous opioids before each infusion is required; triple therapy with a non-opioid analgesic, gabapentin and an opioid is recommended, and the individual dose may vary widely). Non-opioid analgesics such as paracetamol or ibuprofen should be used permanently during treatment. Gabapentin: prime with 10 mg/kg/day starting 3 days before the dinutuximab beta infusion, increase to 2 x 10 mg/kg/day orally the next day and to 3 x 10 mg/kg/day orally the day before the onset of the dinutuximab beta infusion and thereafter, with a maximum single gabapentin dose of 300 mg; maintain for as long as required and taper off after weaning off the intravenous morphine infusion, at the latest after dinutuximab beta therapy has stopped. Morphine: before starting a continuous intravenous morphine infusion, a bolus infusion of 0.02 to 0.05 mg/kg/hour should be started 2 hours before the dinutuximab beta infusion, then a rate of 0.03 mg/kg/hour is recommended concomitantly with the dinutuximab beta infusion; with daily infusions, continue morphine at a decreased rate (e.g. 0.01 mg/kg/hour) for 4 hours after the end of the dinutuximab beta infusion; with continuous infusion it may be possible to wean morphine over 5 days by progressively decreasing the rate (e.g. to 0.02, then 0.01, then 0.005 mg/kg/hour); if continuous morphine is required for more than 5 days, reduce gradually by 20% per day after the last day of dinutuximab beta infusion. After weaning off intravenous morphine, oral morphine sulphate 0.2 to 0.4 mg/kg every 4 to 6 hours can be given on demand for severe neuropathic pain, and oral tramadol may be given for moderate neuropathic pain. Pre-medication should always be considered before starting each infusion. RENAL/HEPATIC IMPAIRMENT: there are no data in patients with renal or hepatic impairment. AGE: safety and efficacy in children aged less than 12 months have not been established and no data are available. TRUNCATION: §4.4 and §4.8 were both cut at the source-fetch limit, so the warnings and adverse-reaction material below is partial — the full warnings (including the remainder of the cytokine release syndrome guidance) and the full adverse-reaction table were not retrieved and must be read from the SPC itself. §4.2 was retrieved complete, so the posology above is not affected.

This is the SPC's own dosing and it is not age-adjusted — the same body-surface-area regimen applies to children and adults. It is expressed per square metre of body surface area, NOT per kilogram, so no dosePerKg value has been set and this figure must never be multiplied by body weight. Safety and efficacy in children aged less than 12 months have not been established and no data are available. Analgesic premedication (gabapentin and morphine, at the per-kilogram rates quoted in the adult notes) is required before each infusion.